Human Papillomavirus Vaccine Market is Poised to Reach USD 9.1 billion by 2031 | Transparency Market Research, Inc.

Another key driver of market increase is government campaigns and initiatives for the production and distribution of HPV vaccinations to stop the virus's spread.

Wilmington, Delaware, United States, Jan. 12, 2024 (GLOBE NEWSWIRE) -- *Transparency Market Research Inc. - *The global *human papillomavirus vaccine market* was projected to attain US$ 4 billion in 2022. It is anticipated *to garner a 9.4% CAGR* from 2023 to 2031 and by 2031, the market is likely to *attain US$ 9.1 billion* by 2031.

Human papillomavirus (HPV) is a widespread virus that affects many different regions of the body. Over two hundred viruses make up the HPV category, of which over forty types are transmitted during intercourse. Sexually transmitted infections (STIs) such as HPV that affect the genitalia are often spread through physical contact.

*Request Sample PDF Report: Empower Your Industry Understanding with Invaluable Insights-**https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=37085 *

Throughout the forecast period, a rise in government efforts is anticipated to support the size of the global market for human papillomavirus vaccines. The creation of new compounds that target HPV presents market participants with profitable potential. To get a larger market share, manufacturers are heavily investing in the creation of novel HPV vaccinations for all age groups.

*Key Findings of the Market Report*

· To stop the spread of the human papillomavirus, governments everywhere are launching a number of campaigns and efforts for the creation and distribution of HPV vaccinations.
· Global distribution of HPV vaccinations as well as screening and immunization programs are funded by both private and public entities.
· According to a January 2023 Vaccines Journal article, Switzerland completely funds the HPV vaccination for girls between the ages of 15 and 26 and for boys between the ages of 11 and 14.

*Market Trends for Human Papillomavirus Vaccine Market*

· The most prevalent sexually transmitted infection (STI) globally is HPV. It is believed that 80% of those who engage in sexual activity have had HPV infection at some point in their life. Over the course of the projection period, an increase in the incidence of HPV-related illnesses such as vaginal, anal, and cervical cancer is anticipated to support demand for the human papillomavirus vaccines globally.
· Cervical cancer is the second most common disease among Indian women, and the second most common among women aged 15 to 44, according to the HPV and Related Cancers report 2023. According to the same source, India diagnoses 123,907 women with cervical cancer annually.

*Global Market for Human Papillomavirus Vaccine: Regional Outlook*

Various reasons are propelling the growth of human papillomavirus vaccine throughout the region. These are:

· In terms of global market share for human papillomavirus vaccines in 2022, North America held the majority of the share. This is attributed to the population's increased incidence of cervical cancer and other HPV-related malignancies as well as the enhanced healthcare infrastructure.
· In the United States, 9,440 new cases of anal cancer were discovered in 2022, according to research released by the American Cancer Society. Furthermore, 1,450 Canadian women had a cervical cancer diagnosis in 2022, according to the Canadian Cancer Society.
· An article in the Human Vaccine and Immunotherapeutic Journal from February 2023 states that HPV vaccinations in the United States can begin as early as age nine and continue until age 26.
· Approximately 77% of teens, aged 13 to 17 have gotten one or more doses of the HPV vaccination, with roughly 62% completing the whole series. The human papillomavirus vaccine market is anticipated to develop significantly in the area due to significant coverage for the HPV vaccination and early screening programs.

*Customize this report according to your needs@ **https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=37085 *

*Global Human Papillomavirus Vaccine Market: Key Players*

The primary objective of major companies is to enhance the efficiency of the adult human papillomavirus vaccination by investing in research and development and launching new products.

These firms are pursuing profitable revenue prospects by staying up to date with the newest developments in the human papillomavirus vaccine industry. The following companies are well-known participants in the global human papillomavirus vaccine market:

· Merck & Co. Inc.
· GlaxoSmithKline plc
· Sanofi
· AstraZeneca
· Serum Institute of India Pvt. Ltd.
· Xiame Innovax Biotech CO. LTD.
· General Incorporated Foundation
· Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
· Bharat Biotech

*Some key developments by the players in this market are:*

· To begin a cervical cancer screening program in India, Roche Diagnostics India and the Cancer Awareness Prevention and Early Detection Trust (CAPED) signed a Memorandum of Understanding (MoU) in March 2023.
· Health Canada approved the expanded use of GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in April 2022 for people 9 to 45 years old in order to protect against infection with Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Merck Canada received this approval.

*Global Human Papillomavirus Vaccine Market Segmentation*

*Valence*

· Bivalent
· Quadrivalent and Nonavalent

*Indication*

· Cervical Cancer
· Anal Cancer
· Vaginal Cancer
· Penile Cancer
· Vulvar Cancer
· Oropharyngeal Cancer
· Genital Warts
· Others

*Distribution Channel*

· Physicians
· Wholesalers
· Physician Distributors
· Government Entities
· Public and Private Alliances

*Region*

· North America
· Latin America
· Europe
· Asia Pacific
· Middle East & Africa

*Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights **https://www.transparencymarketresearch.com/checkout.php?rep_id=37085<ype=S *

*More Trending Report by Transparency Market Research:*

*Vaccines Market** - *The global vaccines market was estimated at a value of *US$ 119.1 billion in 2022*. It is anticipated to register a 4.2% CAGR from 2022 to 2031 and by 2031, the market is likely to attain US$ 99.3 billion by 2031.

*Neurotoxin Market* - The global neurotoxin market stood at US$ 7.78 billion in 2023 and is projected to reach US$ 13.3 billion in 2031. The global neurotoxin market is anticipated to expand *at a CAGR of 6.8%* between 2023 and 2031.

*About Transparency Market Research*

*Transparency Market Research*, a global *market research company* registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

*Contact*:

*Nikhil Sawlani*
*Transparency Market Research Inc.*
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
*Tel:* +1-518-618-1030
*USA – Canada Toll Free*: 866-552-3453
*Website:* *https://www.transparencymarketresearch.com**  *  
*Email:* *sales@transparencymarketresearch.com*

* Follow Us: LinkedIn*| *Twitter*| *Blog* | *YouTube *